gel-e will service multiple large markets in excess of $7B

 

The aging of our society has caused a dramatic escalation in the need for wound treatments. It is estimated that over 20% of the US population will be over 65 by 2020, but will consume >1/3 of all personal healthcare expenses. Driven by the dramamtic increase in the use of blood thinners, older patients more often have compromised coagulative capabilities. Many also suffer from circulatory and immune deficiencies, requiring safer and more routine wound treatment.

These markets, already in excess of $7B, are in desperate need of cost effective solutions. gel-e offers products that can be easily applied by both trained healthcare professionals and the average senior citizen that provide almost instantaneous clotting while creating a sturdy barrier under which the wound can heal.

products* status, intended market market value

Sprayable foams for traumatic, non-compressible hemorrhage.

$100M

FDA cleared for the management of bleeding wounds including post-operative vascular and radial access procedures with planned expansion to broad OTC & Rx use.

$500M

For broad OTC & Rx use, including internal surgical applications.

$2B+

Films for treatment of heavily exudating chronic wounds and venous leg ulcers.

$2.7B

High performance first aid kits including next generation band-aids, gel-e pens and gel-e foams.

$3B

*Not yet commercially available
K143466
Indicated for use, under the direction of a healthcare professional, in the management of bleeding wounds such as vascular access sites and percutaneous catheters or tubes.